Companies
Healthgen Biotech
its OsrHSA injection (奥福民®) became the world's first NMPA-approved rHSA therapeutic injection in July 2025 — also the first globally-approved rice-derived recombinant protein drug — backed by a multicentre, randomised, double-blind,…
- Country
- China
- Ticker
- SSE:688765
World's first NMPA-approved rHSA injection; first globally-approved rice-derived recombinant protein drug
cn
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | raised approximately RMB 2.6 billion (approx. $366 million) in an October 2025 IPO on the Shanghai Stock Exchange STAR Market | biobase.whitefordresearch.com · dehenglaw.com |
| Funding | secured RMB 556.3155 million (approx. $87.6 million) in a Pre-IPO financing round in February/March 2022 | biobase.whitefordresearch.com |
| Capacity | 10 tons of HSA stock solution annually, with a total capacity planned to rise to 130 tons in 2026 | english.wuhan.gov.cn · chinadaily.com.cn |
| Capacity | 1 million doses of formulations annually, with plans to increase to 12 million doses | regional.chinadaily.com.cn |
| Certification | obtained a drug manufacturing certificate from the Hubei medical products administration | regional.chinadaily.com.cn · static.cninfo.com.cn |
| Regulatory approval | received NMPA approval for its rice-derived recombinant human albumin injection (OsrHSA/HY1001) in July 2025 | cen.acs.org · static.cninfo.com.cn · chinadaily.com.cn |
| Production site | headquartered in the East Lake High-Tech Development Zone, Wuhan, China, with production facilities including a cGMP-compliant smart manufacturing base | static.cninfo.com.cn |
Independent sources: biobase.whitefordresearch.com · cen.acs.org · chinadaily.com.cn · dehenglaw.com · english.wuhan.gov.cn · regional.chinadaily.com.cn · static.cninfo.com.cn
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant human serum albumin (rHSA) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.